Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

957 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.
Leonardi S, Tricoci P, White HD, Armstrong PW, Huang Z, Wallentin L, Aylward PE, Moliterno DJ, Van de Werf F, Chen E, Providencia L, Nordrehaug JE, Held C, Strony J, Rorick TL, Harrington RA, Mahaffey KW. Leonardi S, et al. Among authors: white hd. Eur Heart J. 2013 Jun;34(23):1723-31. doi: 10.1093/eurheartj/eht104. Epub 2013 Mar 25. Eur Heart J. 2013. PMID: 23530022 Clinical Trial.
The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes.
Savonitto S, Granger CB, Ardissino D, Gardner L, Cavallini C, Galvani M, Ottani F, White HD, Armstrong PW, Ohman EM, Pieper KS, Califf RM, Topol EJ; GUSTO-IIb Investigators. Savonitto S, et al. Among authors: white hd. J Am Coll Cardiol. 2002 Jan 2;39(1):22-9. doi: 10.1016/s0735-1097(01)01706-5. J Am Coll Cardiol. 2002. PMID: 11755282 Free article.
Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries.
Anderson RD, White HD, Ohman EM, Wagner GS, Krucoff MW, Armstrong PW, Weaver WD, Gibler WB, Stebbins AL, Califf RM, Topol EJ. Anderson RD, et al. Among authors: white hd. Am Heart J. 2002 Jul;144(1):81-8. doi: 10.1067/mhj.2002.123319. Am Heart J. 2002. PMID: 12094192 Clinical Trial.
Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes.
Al-Khatib SM, Granger CB, Huang Y, Lee KL, Califf RM, Simoons ML, Armstrong PW, Van de Werf F, White HD, Simes RJ, Moliterno DJ, Topol EJ, Harrington RA. Al-Khatib SM, et al. Among authors: white hd. Circulation. 2002 Jul 16;106(3):309-12. doi: 10.1161/01.cir.0000022692.49934.e3. Circulation. 2002. PMID: 12119245
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, Guetta V, Gibler WB, Hochman JS, Bode C, Vahanian A, Steg PG, Ardissino D, Savonitto S, Bar F, Sadowski Z, Betriu A, Booth JE, Wolski K, Waller M, Topol EJ; Global Use of Strategies To Open Coronary Arteries Investigators (GUSTO). Lincoff AM, et al. Among authors: white hd. JAMA. 2002 Nov 6;288(17):2130-5. doi: 10.1001/jama.288.17.2130. JAMA. 2002. PMID: 12413372 Clinical Trial.
Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone.
O'Shea JC, Wilcox RG, Skene AM, Stebbins AL, Granger CB, Armstrong PW, Bode C, Ardissino D, Emanuelsson H, Aylward PE, White HD, Sadowski Z, Topol EJ, Califf RM, Ohman EM. O'Shea JC, et al. Among authors: white hd. Am J Cardiol. 2002 Dec 15;90(12):1374-7. doi: 10.1016/s0002-9149(02)02876-x. Am J Cardiol. 2002. PMID: 12480048 Clinical Trial. No abstract available.
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf RM, Topol EJ. Mukherjee D, et al. Among authors: white hd. Am Heart J. 2002 Dec;144(6):995-1002. doi: 10.1067/mhj.2002.126118. Am Heart J. 2002. PMID: 12486423 Clinical Trial.
957 results